Since the normalization of drug collection, the collection of proprietary Chinese medicines has always attracted the attention of
the industry.
On September 9, the National Federation of Proprietary Chinese Medicines Office issued the "National Alliance of Proprietary Chinese Medicines Procurement Announcement (No.
1 of 2022)", which collected a total of 16 kinds of proprietary Chinese medicines such as compound cantharid, compound thrombosis, coronary xinning, and Hua toxin
.
The announcement shows that the National Joint Procurement Office of Proprietary Chinese Medicines is composed of representatives appointed by 30 alliance regions such as Hubei Province and Beijing Municipality, and for this round of collection of proprietary Chinese medicines, all public medical institutions (including military medical institutions) in the alliance area should participate, and medical insurance designated social medical institutions and designated pharmacies are encouraged to participate in accordance with the relevant regulations of
the alliance area.
The procurement cycle is 2 years and may be extended
as appropriate.
The purchase agreement is signed once a year in the procurement cycle, and if the purchase volume of the current year's agreement is completed in advance during the procurement cycle, the selected enterprises in excess of the purchase period will still supply at the selected price until the expiration
of the procurement cycle.
During the procurement cycle, for the products that are not selected, they will be included in the monitoring and management of the alliance area, and the procurement of unselected products by medical institutions shall not exceed 10%
of the actual procurement volume of the same procurement group.
The industry believes that from the perspective of the 16 kinds of proprietary Chinese medicines selected in this collection, they are all more representative and clinically used varieties, which can achieve price for volume, and also have more value of quality assurance, and it is expected that the competition of enterprises in the collection and procurement negotiations will be more intense
.
After the collection and procurement of the Chinese Patent Medicine Alliance, it may have a certain impact on the hospital, such as the lack of supply of the winning bidder will affect the continuity of the hospital, but the overall impact is small
.
In addition, the collection will also lead to a significant improvement in the level of rational use of clinical Chinese medicine nationwide, and expand a wider range of drug use scenarios
.
For the collection of proprietary Chinese medicines, in fact, the industry is no longer unfamiliar
.
Previously, a round of collection of proprietary Chinese medicines alliances has been carried out nationwide
.
In December 2021, Hubei led the 19 provinces (autonomous regions and municipalities) alliance of proprietary Chinese medicines to open bids for centralized procurement, and 182 products from 157 enterprises participated in the quotation, with a procurement scale of nearly 10 billion yuan
.
The results show that a total of 97 companies and 111 products were selected, with a selection rate of 62%, and the average price of the selection was 42.
27%, of which the high decline reached 82.
63%.
According to the annual demand of the 19 provinces (autonomous regions and municipalities) alliance, it is expected to save more than 2.
6 billion yuan in drug costs per year, which is also the first centralized procurement
of the national alliance of proprietary Chinese medicines.
In addition to the alliance collection led by Hubei, Guangdong has also carried out the collection of proprietary Chinese medicine alliances, Shandong Province has launched a special collection of proprietary Chinese medicines, and in addition, the procurement of proprietary Chinese medicines in Beijing has also been officially launched
not long ago.
It can be seen that the collection of proprietary Chinese medicines has been promoted
in many places.
For proprietary Chinese medicine enterprises, they are not only facing the promotion of collection, but also affected by the rising prices of Chinese herbal medicines and the tightening of quality requirements, and are facing the pressure of cost control and how to improve quality
.
Some industry insiders expect that with the advancement of the collection of proprietary Chinese medicines, the price of Chinese herbal medicines may further rise, which may stimulate the collection of raw materials at the front end
.
In the long run, the chinese patent medicine market can not avoid the reshuffle, the industry believes that it will be good for the head of the enterprise with the cost of ownership and variety advantages, and the industry concentration is expected to continue to optimize, helping the entire industry to establish a unified quality assurance system, which is conducive to future work
.
